Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 8, 2019. The report disseminates a London Stock Exchange announcement issued on March 7, 2019, regarding ViiV Healthcare, a global specialist HIV company established by GSK, Pfizer, and Shionogi. The filing details positive 48-week data from two pivotal Phase III studies (ATLAS and FLAIR) concerning an investigational long-acting injectable HIV regimen.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is a clinical trial update and does not contain financial statements or quantitative financial data.
Material Changes and Clinical Results
The primary material update is the successful completion of primary endpoints in two Phase III studies for a long-acting, injectable two-drug regimen of cabotegravir and rilpivirine:
- ATLAS Study: Demonstrated non-inferiority to a standard daily oral three-drug regimen. Virologic suppression rates at Week 48 were 92.5% for the injectable regimen versus 95.5% for the oral control. Confirmed virologic failure occurred in approximately 1% of the injectable group.
- FLAIR Study: Demonstrated non-inferiority to Triumeq (oral three-drug regimen). Virologic suppression rates at Week 48 were 93.6% for the injectable regimen versus 93.3% for Triumeq. Confirmed virologic failure occurred in approximately 1% of the injectable group.
- Safety and Tolerability: Both studies reported low rates of serious adverse events (4.2% in ATLAS, 6.4% in FLAIR). Injection site reactions (ISRs) were common (83% in ATLAS, 86% in FLAIR) but predominantly mild or moderate, with a median duration of three days.
- Patient Preference: Significant preference was observed for the injectable regimen over oral therapy, with 86.4% of ATLAS participants and 90.8% of FLAIR participants preferring the injectable option.
Outlook, Risks, and Contingencies
Outlook and Management Commentary: ViiV Healthcare plans to submit applications to regulatory authorities later in 2019 based on these data. Management highlighted the potential to shift HIV treatment from 365 daily doses to 12 monthly doses, significantly improving patient satisfaction and adherence. The company is also investigating a two-month dosing schedule in the ATLAS-2M study.
Risks and Contingencies:
- Resistance Patterns: An unexpected pattern of confirmed virologic failure with resistance mutations was observed in three participants in each study. All six individuals were from Russia and had HIV-1 subtype A1. Management noted this warrants further investigation.
- Regulatory Status: The investigational long-acting injectable regimen is not approved by regulatory authorities anywhere in the world.
- Forward-Looking Statements: GSK cautions that actual results may differ materially from projections due to risks described in their Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the timeline for regulatory submissions to the FDA and EMA following the March 2019 data presentation.
- Monitor further analysis regarding the unexpected resistance mutations observed in Russian participants with HIV-1 subtype A1.
- Review the commercial partnership terms between ViiV Healthcare and Janssen Sciences Ireland UC regarding the co-development of rilpivirine.
- Assess the potential market impact of shifting from daily oral therapy to monthly injectable therapy on GSK's HIV portfolio revenue.
- Confirm the status of the ATLAS-2M study evaluating a two-month dosing interval.